Skip to main content
Signal8

Oltmans Curtis Gale

SEC insider (Form 3/4/5 filer). CIK 0001714982. Chief Legal Officer at Fulcrum Therapeutics, Inc. (FULC) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Feb 2, 2026. Located in CAMBRIDGE, MA.

Companies Oltmans Curtis Gale has filed insider reports for

  • Fulcrum Therapeutics, Inc. (FULC): Officer, Chief Legal Officer
  • AVENUE THERAPEUTICS, INC. (ATXI): Director
Oltmans Curtis Gale profile photo

Oltmans Curtis Gale

CIK: 0001714982

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (25.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

Fulcrum Therapeutics, Inc. logo
FULC

Fulcrum Therapeutics, Inc.

Officer
AVENUE THERAPEUTICS, INC. logo
ATXI

AVENUE THERAPEUTICS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

  • Fulcrum Therapeutics, Inc. logo
    FULC

    Fulcrum Therapeutics, Inc.

    Feb 2, 2026
    Award

    Stock Option (right to buy)

    Direct
    170K shares-
  • Fulcrum Therapeutics, Inc. logo
    FULC

    Fulcrum Therapeutics, Inc.

    Dec 15, 2025
    Sale
    Direct
    3.5K shares at avg. $12.92$45K
  • Fulcrum Therapeutics, Inc. logo
    FULC

    Fulcrum Therapeutics, Inc.

    Jan 24, 2025
    Award

    Stock Option (right to buy)

    Direct
    225K shares-
  • AVENUE THERAPEUTICS, INC. logo
    ATXI

    AVENUE THERAPEUTICS, INC.

    Sep 23, 2024
    Award

    Employee stock option (right to buy)

    Direct
    30K shares-

1-4 of 4